MaxCyte® acquires SeQure Dx to broaden cell engineering offerings with on-target and off-target editing assessments

MaxCyte, Inc., a leading, cell-engineering focused company providing solutions to advance the discovery, development and commercialization of next-generation cell therapeutics announced today the acquisition of SeQure Dx, a market leader of on-target and off-target editing assessment services for cell and gene therapies.

Oramed Pharmaceuticals sees highest filings and grants during April in Q2 2024

Oramed Pharmaceuticals has been focused on protecting inventions in Denmark(DK) with one publication in Q2 2024 The Denmark(DK) Patent Office dominates the patent filings with

July 21, 2024

New antibody targets cancer-causing HER2 mutations

For some proteins, a single mutation, or change in its DNA instructions, is all it takes to tip the balance between functioning normally and causing

October 22, 2024

J&J trims pipeline, including two mid-stage neuroscience studies

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

October 16, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.